IRIX earnings: next report 2026-08-18, real EPS beat/miss history, analyst consensus Buy, P/E -4.82. Updated 2026-07-23.
IRIDEX (IRIX) Research Hub
IRIDEX (IRIX) trades on NASDAQ, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 0.66 USD (-2.94%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.82, market cap 0.02B. This hub links to the full technical, earnings and options research available for IRIX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.66 USD (-2.94%) |
| 52-week range | 0.6524 USD – 1.2 USD |
| Trend regime | Range |
| 14-day RSI | 30.9 (Bearish) |
| Trailing P/E | -4.82 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-18 |
Available research for IRIX
Covered Call on IRIX: how it works, illustrative setup around the real 0.66 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on IRIX: how it works, illustrative setup around the real 0.66 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on IRIX: how it works, illustrative setup around the real 0.66 USD price, max profit/loss, breakeven and when to use it. Educational.
IRIX technical analysis: range, last 0.66 USD, RSI 30.9, 52w range 0.6524 USD–1.2 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is IRIX in?
IRIDEX (IRIX) is classified under Healthcare (Medical - Devices), listed on NASDAQ, US.
Is IRIX in an uptrend or downtrend?
As of 2026-09-11, IRIX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is IRIX's trailing P/E ratio?
IRIX's trailing P/E is -4.82, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does IRIX next report earnings?
IRIX is next scheduled to report earnings on 2026-08-18, with a consensus EPS estimate of -0.01 USD.